Maze Therapeutics (MAZE) CSBO reports option grants and stock sales
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Maze Therapeutics, Inc. chief business and strategy officer Atul Dandekar reported a mix of equity awards, option exercise, and share sales. He received a grant of 38,000 stock options and 19,000 restricted stock units, each at an exercise or acquisition price of $0.00 per share.
On February 27, 2026, he exercised 7,500 stock options at $10.42 per share to acquire 7,500 shares of common stock, then sold 3,739 shares at a weighted average price of $45.134 and 3,761 shares at $45.7238. The sales were made under a Rule 10b5-1 trading plan adopted on September 29, 2025.
Following these transactions, he directly held 10,503 shares of common stock, 59,143 stock options and 19,000 restricted stock units. The new option award vests in 1/48 increments monthly starting April 1, 2026, while the RSUs vest in four annual tranches beginning March 1, 2027.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 7,500 shares ($340,723)
Net Sell
6 txns
Insider
Dandekar Atul
Role
CSBO
Sold
7,500 shs ($341K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 38,000 | $0.00 | -- |
| Grant/Award | Restricted Stock Units | 19,000 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 7,500 | $0.00 | -- |
| Exercise | Common Stock | 7,500 | $10.42 | $78K |
| Sale | Common Stock | 3,739 | $45.134 | $169K |
| Sale | Common Stock | 3,761 | $45.7238 | $172K |
Holdings After Transaction:
Stock Option (Right to Buy) — 38,000 shares (Direct);
Restricted Stock Units — 19,000 shares (Direct);
Common Stock — 18,003 shares (Direct)
Footnotes (1)
- This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.55 to $45.54 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.55 to $46.02 per share, inclusive. The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025. The option award shall vest as to 1/48 of the total award monthly, with the first tranche vesting on April 1, 2026, subject to the reporting person's continued service to the Issuer on each vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The restricted stock unit award shall vest in ratable increments of 1/4 of the total award, with the first tranche vesting on March 1, 2027, and vesting thereafter on the one year anniversary of such date, subject to the reporting person's continued service to the Issuer on each vesting date. These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date.
FAQ
What insider transactions did Atul Dandekar report for Maze Therapeutics (MAZE)?
Atul Dandekar reported new equity awards, an option exercise, and share sales. He received 38,000 stock options and 19,000 restricted stock units, exercised 7,500 options into common stock, and sold 7,500 shares in two tranches under a pre-arranged Rule 10b5-1 trading plan.
What new equity awards did Maze Therapeutics grant Atul Dandekar in this Form 4?
Maze Therapeutics granted him 38,000 stock options and 19,000 restricted stock units. The options were issued with a $0.00 exercise price and vest monthly over 48 months, while the RSUs vest in four equal annual installments starting March 1, 2027, subject to continued service.
How do the new Maze Therapeutics stock options granted to Atul Dandekar vest?
The 38,000 Maze Therapeutics stock options vest in equal monthly installments. Specifically, 1/48 of the award vests each month, with the first tranche vesting on April 1, 2026, contingent on Atul Dandekar’s continued service to the company on each vesting date.
What is the vesting schedule for Atul Dandekar’s new Maze Therapeutics RSUs?
The 19,000 restricted stock units vest over four years. One quarter of the award vests on March 1, 2027, and the remaining three quarters vest on each one-year anniversary of that date, assuming his continued service to Maze Therapeutics at each vesting date.